Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss

New probe presented astatine the yearly gathering of the European Association for the Study of Diabetes (EASD) successful Milan, Italy, Sept. 28–Oct. 2, and successful property astatine The Lancet shows that trevogrumab, which inhibits a macromolecule that negatively regulates musculus mass, tin trim thin wide nonaccomplishment during semaglutide attraction by 50% compared with semaglutide and placebo.